Health

Healthcare Economist Unbiased Analysis of Today’s Healthcare Issues

  • Quantifying the Lifetime Economic Impact of Pediatric Oral Nutritional Supplements
    by Jason Shafrin on April 10, 2026 at 12:52 am

    That is the title of a new paper published this week in Clinical Nutrition with co-authors Kyi-Sin Than, Khounish Sharma, Kirk W. Kerr, and Dhanasekhar Kesavelu. The abstract is below: IntroductionPediatric malnutrition is a significant global public health challenge, particularly in low- and middle-income countries. This study quantifies the lifetime, per-person economic impact of pediatric…

  • Life expectancy in Panama is better than in the US
    by Jason Shafrin on April 3, 2026 at 6:02 am

    I am traveling to Panamá this Friday. Here are some interesting facts about the country’s health care system. Life expectancy is better than the U.S. Life expectancy in Panamá is 79.59 compared to 79.30 in the U.S. Mix of public and private health insurance. Panama’s healthcare architecture rests on two distinct public pillars. The Caja de…

  • Links
    by Jason Shafrin on April 3, 2026 at 5:25 am

    Role of health care in the 2026 election. Where does economics fall in terms of study reproducibility? COVID-19’s “cicada” variant is spreading Best practices for transparent reporting for group based trajectory models. What is “learned helplessness”?

  • What has been the main impact of MFN?
    by Jason Shafrin on April 1, 2026 at 5:07 am

    It is not bringing down US prices, but delaying launches in Europe. Reuters reports: Drug launches in EU markets fell by some 35% in the 10 months since Trump’s executive order, compared with the previous ​10 months…Delaying launches at lower EU prices could help secure higher U.S. prices for longer. You can read the full…

  • How did China become a global leader in life sciences?
    by Jason Shafrin on March 31, 2026 at 5:14 am

    An NBER working paper by Barwick, Xia and Xia (2026) provides the answer: In 2010, China accounted for less than 8% of global clinical trials; by 2020, it had surpassed the US in annual registered clinical trial volume…We provide strong evidence that China’s rise was primarily driven by the National Reimbursement Drug List (NRDL) reform,…